Unlocking the Potential of NS2 Gene: A Promising Drug Target for HCV Treatment

Authors

  • Hina Abbasi Lecturer, Department of Biomedical Engineering, Sir Syed University of Engineering and Technology, Pakistan, Author
  • Wajiha Zafar Abbas Department of Biochemistry, University of Karachi, Author
  • Sana Ahmad Assistant Professor, Department of Biochemistry, Bahria University Health Sciences Campus Karachi, Pakistan, Author
  • Mahvish Sultan Lecturer, Department of Biomedical Engineering, Sir Syed University of Engineering and Technology Author
  • Sidra Abid Syed Professor, Department of Biomedical Engineering, Sir Syed University of Engineering and Technology, Pakistan Author
  • Ambreen Hasnat Assistant Professor, Department of Biomedical Engineering, Sir Syed University of Engineering and Technology, Pakistan Author
  • Darakhshan Saleem Associate Professor, Department of Biomedical Engineering, Sir Syed University of Engineering and Technology, Pakistan Author
  • Bushra Jabeen Mehdi Associate Professor, Department of Biomedical Engineering, Sir Syed University of Engineering and Technology, Pakistan Author

Abstract

 Hepatitis C becomes life threatening disease. It is 5 times more prevalent than HIV. Hepatitis C is a blood-borne virus that predominately infects the cells of the liver. The hepatitis C virus (HCV) is a small, enveloped, single-stranded, positive-sense RNA virus. The proteins of HCV consist of structural and non-structural genes. Non-structural 2 (NS2) gene is transmembrane protein containing an autoprotease responsible for cis cleavage at the NS2-NS3 junction within its C-terminal domain. NS2 is uniquely capable of interacting with both structural and nonstructural proteins. Non-structural protein 2 (NS2) performs main role in hepatitis C virus (HCV) meeting, however neither the designated contribution of this protein to the meeting procedure nor its whole constitution are identified. NS2 additionally performs a primary position within the production of infectious particles however the mechanism is unknown. The information received from the study would illustrate the structure and function interaction of NS2 gene. This may intermittently augment our understanding of ailment biology of HCV associated infections. This study is expected to make contributions in learning molecular mechanism of NS2 gene of HCV. 

Downloads

Download data is not yet available.

References

Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., O’hUigin, C., ... & Goedert, J.

J. (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C

virus. Nature, 461(7265), 798-801.

Sadia Butt, Muhammad Idrees, Irshad Ur Rehman, Haji Akbar, Muhammad

Shahid, Samia Afzal, Saima Younas, and Iram Amin (2011) Emerg HYPERLINK

"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381542/" Infect Dis. 1565–1567.

Nakano, T., Lau, G. M., Lau, G. M., Sugiyama, M., & Mizokami, M. (2012). An updated

analysis of hepatitis C virus genotypes and subtypes based on the complete coding

region. Liver international : official journal of the International Association for the Study

of the Liver, 32(2), 339–345. https://doi.org/10.1111/j.1478-3231.2011.02684.x

Carla Kuiken, Karina Yusim, Laura Boykin, Russell Richardson, The Los Alamos

hepatitis C sequence database, Bioinformatics, Volume 21, Issue 3, 1 February 2005,

Pages 379–384.

Simmonds P. (2004). Genetic diversity and evolution of hepatitis C virus--15 years

on. The Journal of general virology, 85(Pt 11), 3173–3188.

https://doi.org/10.1099/vir.0.80401-0.

Bruce R. Bacon, M.D., Stuart C. Gordon, M.D., Eric Lawitz, M.D., Patrick Marcellin,

M.D., John M. Vierling, M.D., Stefan Zeuzem, M.D., Fred Poordad, M.D., Zachary D.

Goodman, M.D., Ph.D., Heather L. Sings, Ph.D., Navdeep Boparai, M.S., Margaret

Burroughs, M.D., Clifford A. Brass, M.D., Ph.D., Janice K. Albrecht, Ph.D., and Rafael

Esteban, M.D. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection.

The new England Journal of Medicine. 2011; 364:1207-1217.

Palumbo E. (2011). Pegylated interferon and ribavirin treatment for hepatitis C virus

infection. Therapeutic advances in chronic disease, 2(1), 39–45.

https://doi.org/10.1177/2040622310384308.

Binder M, Sulaimanov N, Clausznitzer D, Schulze M, Hüber CM, Lenz SM, et al. (2013)

Replication Vesicles are Load- and Choke-Points in the Hepatitis C Virus Lifecycle.

PLoS Pathog 9(8): e1003561. https://doi.org/10.1371/journal.ppat.1003561.

D.S. Dane, C.H. Cameron, M. Briggs. Lancet, 1 (1970), p. 695. Gerin and Shih, 1978.

J.L. Gerin, J.W.-K. ShihViral Hepatitis. G.N. Vyas, S.N. Characterization of hepatitis B

virus (Dane particle). Journal of Virological Methods, Volume 1, Issue 1, March 1980,

Pages 47-59

Rizzetto M. (2015). Hepatitis D Virus: Introduction and Epidemiology. Cold Spring

Harbor perspectives in medicine, 5(7), a021576.

https://doi.org/10.1101/cshperspect.a021576

Maillard, P., Krawczynski, K., Nitkiewicz, J., Bronnert, C., Sidorkiewicz, M., Gounon,

P., Dubuisson, J., Faure, G., Crainic, R., & Budkowska, A. (2001). Nonenveloped

nucleocapsids of hepatitis C virus in the serum of infected patients. Journal of

virology, 75(17), 8240–8250.

Li, C., Cao, H., Lu, L., & Murphy, D. (2012). Full-length sequences of 11 hepatitis C

virus genotype 2 isolates representing five subtypes and six unclassified lineages with

unique geographical distributions and genetic variation patterns. The Journal of general

virology, 93(Pt 6), 1173–1184. https://doi.org/10.1099/vir.0.038315-0.

Julieta Trinks, Adrian Gadano, & Pablo Argibay (2012). Evolving Trends in the Hepatitis

C Virus Molecular Epidemiology Studies: From the Viral Sequences to the Human

Genome. Epidemiology Research International Volume 2012.

Li, C., Njouom, R., Pépin, J., Nakano, T., Bennett, P., Pybus, O. G., & Lu, L. (2013).

Characterization of full-length hepatitis C virus sequences for subtypes 1e, 1h and 1l, and

a novel variant revealed Cameroon as an area in origin for genotype 1. The Journal of

general virology, 94(Pt 8), 1780–1790. https://doi.org/10.1099/vir.0.048835-0.

El Makarem, M. A. A., Abdel-Aleem, A., Ali, A., Saber, R., Shatat, M., Rahem, D. A., &

Sayed, D. (2016). Diagnostic significance of plasma osteopontin in hepatitis C virusrelated hepatocellular carcinoma. Annals of hepatology, 10(3), 296-305.

Downloads

Published

2024-04-30

Issue

Vol. 10 No. 2 (2024): 10 (2) 2024

Section

Articles

License

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

Abbasi, H., Zafar Abbas, W., Ahmad, S., Sultan, M., Abid Syed, S., Hasnat, A., Saleem, D., & Jabeen Mehdi, B. (2024). Unlocking the Potential of NS2 Gene: A Promising Drug Target for HCV Treatment. History of Medicine, 10(2), 557-591. https://historymedjournal.com/HOM/index.php/medicine/article/view/817